King Pharmaceuticals, Wyeth amend Altace agreement

King Pharmaceuticals and Wyeth have amended and restated their co-promotion agreement for King's Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor to treat high blood pressure. Effective Jan. 1, 2007, King will assume full responsibility for the selling and marketing of Altace. For the remainder of 2006, the Wyeth sales force will continue to promote the product with King, and Wyeth will receive a fee thereafter through 2010.
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical